Our Services
Medical Information
Helpful Resources
Published on: 9/22/2026
Zyprexa (olanzapine) is an atypical antipsychotic prescribed primarily for schizophrenia and bipolar I disorder, and it is also used in combination with fluoxetine for treatment-resistant depression. Weight gain is one of its most common and well-documented side effects, often paired with increased appetite, elevated blood sugar, and changes in cholesterol levels. How much weight a person gains varies by dose, length of treatment, age, and baseline metabolic health, and there are several important details to consider below, including monitoring schedules and management strategies. If you are noticing unexplained weight changes, mood shifts, or other new symptoms, a free, instant, online <a href="https://ubi
What Is Zyprexa Used For?
Zyprexa (generic name: olanzapine) is an antipsychotic medication commonly prescribed to manage certain mental health conditions. Approved by the U.S. Food and Drug Administration (FDA), it belongs to the second-generation (atypical) antipsychotics. Its primary uses include:
How Zyprexa Works
Zyprexa influences brain chemistry by blocking certain receptors:
By modulating these neurotransmitters, Zyprexa helps stabilize thinking, reduce agitation and improve overall mood regulation.
Dosage Forms and Administration
Zyprexa is available in several forms:
Doctors typically start with a low dose (e.g., 5–10 mg daily) and adjust based on response and tolerability. Daily dosing at the same time helps maintain stable blood levels.
Common Side Effects
While many people take Zyprexa without serious problems, it can cause side effects. Common reactions include:
Among these, weight gain and metabolic changes are especially important to monitor.
Does Zyprexa Cause Weight Gain?
Yes. Significant weight gain is a well-documented concern with Zyprexa:
Health Risks of Excess Weight Gain
Uncontrolled weight gain can contribute to:
Because of these risks, the FDA requires monitoring of weight, fasting blood glucose and lipid profiles before starting therapy and at regular intervals during treatment.
Strategies to Manage and Minimize Weight Gain
If you or your doctor decide Zyprexa is necessary, consider these approaches to limit weight gain and metabolic impact:
• Baseline Assessment
– Measure weight, body mass index (BMI), waist circumference, fasting glucose and lipid panel.
• Nutrition and Diet
– Aim for balanced meals rich in vegetables, lean protein and whole grains.
– Limit sugary drinks, processed foods and high-fat snacks.
– Keep a food diary or use a mobile app to track calorie intake.
• Regular Physical Activity
– At least 150 minutes per week of moderate aerobic exercise (e.g., brisk walking, cycling).
– Strength training 2 times per week to boost metabolism.
• Behavioral Support
– Work with a dietitian or join a weight-management program.
– Practice mindful eating: focus on hunger/fullness cues and avoid emotional eating.
• Medication Review
– If weight gain is severe, discuss with your doctor the possibility of switching to a different antipsychotic with a lower risk of metabolic side effects (e.g., aripiprazole or ziprasidone).
Monitoring While on Zyprexa
To catch problems early, follow these guidelines:
If you notice troubling symptoms or rapid weight gain, schedule a follow-up with your healthcare provider.
When to Seek Immediate Medical Help
Although most side effects are manageable, some may require urgent attention:
If any of these occur, seek emergency care or contact your doctor right away.
Taking Charge of Your Health
If you’re experiencing new symptoms or aren’t sure whether Zyprexa is right for you, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you sort out whether your symptoms warrant medical evaluation or an office visit.
Key Takeaways
This information is meant to be a comprehensive overview, but it doesn’t replace personalized medical advice. If you experience severe or life-threatening symptoms—or if you have any doubts about your treatment—please speak to a doctor right away.
(References)
* Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry. 1997;58 Suppl 10:13-7. PMID: 9265911.
* Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B. Olanzapine-induced weight gain. Ann Clin Psychiatry. 1998 Mar;10(1):39. doi: 10.1023/a:1026154730108. PMID: 9622049.
* Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine-induced glucose dysregulation. Ann Pharmacother. 2000 Jul-Aug;34(7-8):865-7. doi: 10.1345/aph.19327. PMID: 10928397.
* Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209-23. doi: 10.1056/NEJMoa051688. Epub 2005 Sep 19. PMID: 16172203.
* Barak N, Beck Y, Albeck JH. Betahistine decreases olanzapine-induced weight gain and somnolence in humans. J Psychopharmacol. 2016 Mar;30(3):237-41. doi: 10.1177/0269881115626349. Epub 2016 Feb 2. PMID: 26839321.
* Paik J. Olanzapine/Samidorphan: First Approval. Drugs. 2021 Aug;81(12):1431-1436. doi: 10.1007/s40265-021-01568-0. PMID: 34304374.
* Muratore AF, Attia E. Psychopharmacologic Management of Eating Disorders. Curr Psychiatry Rep. 2022 Jul;24(7):345-351. doi: 10.1007/s11920-022-01340-5. Epub 2022 May 16. PMID: 35576089; PMCID: PMC9233107.
* Ferreira V, Folgueira C, Guillén M, Zubiaur P, Navares M, Sarsenbayeva A, López-Larrubia P, Eriksson JW, Pereira MJ, Abad-Santos F, Sabio G, Rada P, Valverde ÁM. Modulation of hypothalamic AMPK phosphorylation by olanzapine controls energy balance and body weight. Metabolism. 2022 Dec;137:155335. doi: 10.1016/j.metabol.2022.155335. Epub 2022 Oct 19. PMID: 36272468.
* Sandhya L, Devi Sreenivasan N, Goenka L, Dubashi B, Kayal S, Solaiappan M, Govindarajalou R, Kt H, Ganesan P. Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer. J Clin Oncol. 2023 May 10;41(14):2617-2627. doi: 10.1200/JCO.22.01997. Epub 2023 Mar 28. PMID: 36977285.
* Zhu T, Zhao H, Chao Y, Gao S, Dong X, Wang Z. Olanzapine-induced weight gain and lipid dysfunction in mice between different gender. Biomed Chromatogr. 2024 Jun;38(6):e5864. doi: 10.1002/bmc.5864. Epub 2024 Mar 29. PMID: 38551083.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.